Information barriers to the implementation of economic evaluations in Japan

PharmacoEconomics

Volumn 20, Issue SUPPL. 2, 2002, Pages 9-15

  Nishimura, Shuzo ^a   Torrance, George W ^b,c,d   Ikegami, Naoki ^e   Fukuhara, Shunichi ^a   Drummond, Michael ^f,g   Schubert, François ^h  

^a KYOTO UNIVERSITY   (Japan)

^b MCMASTER UNIVERSITY   (Canada)

^c i3 Global   (Canada)

^d Health Utilities Incorporated   (Canada)

^e KEIO UNIVERSITY   (Japan)

^f UNIVERSITY OF YORK   (United Kingdom)

^g Innovus Research UK   (United Kingdom)

^h INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; COST CONTROL; DRUG INDUSTRY; ECONOMIC EVALUATION; EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; JAPAN; MEDICAL TECHNOLOGY; PRIORITY JOURNAL;

EID: 0036377674     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220002-00002     Document Type: Conference Paper

References (11)

1. Integrating economic evaluations and quality of life assessments
2. A comparative review of pharmacoeconomic guidelines
3. Guidelines for authors and peer reviewers of economic submissions to the BMJ
4. Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?
5. Economic evaluation of neonatal intensive care of very-low-birth-weight infants
6. The Canadian model for the establishment of guidelines
7. Canada's new guidelines for the economic evaluation of pharmaceuticals
8. The revised Canadian guidelines for the economic evaluation of pharmaceuticals